ClinicalTrials.gg
Active, not recruitingNCT06063148Neo-PODSUpdated May 18, 2026

Neonatal Pulse Oximetry Disparities Due to Skin Pigmentation

An interventional study of Enrolled Participant in Skin Pigment and Pulse Oximetry, sponsored by University of California, Davis. Active, not recruiting at 2 sites in United States. Open to participants aged Up to 10 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by University of California, Davis · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Apr 2022, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
163
Allocation
Not applicable
Ages
Up to 10 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Pigmentation Disorders with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Pigmentation Disorders · United States.

Planned enrollment
2nd of 18
163 · median 31
Started
2022
with 3 others
No phase
11 of 25
1 open now
Registered
18th of 25
by date
Lead sponsor
3 of 25
University of California, Davis

Among the 25 studies in Pigmentation Disorders with a site in United States, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 with no phase, and was the 18th registered.

Pigmentation Disorders

57 studies on the registry are indexed under Pigmentation Disorders; 12 are open to participants now.

Browse Pigmentation Disorders studies →

Open to participants now

7 of the 25 studies in Pigmentation Disorders with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Pigmentation Disorders studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: Up to 10 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pigmentation Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine if pulse oximeters show an SaO2-SpO2 discrepancy that correlates with skin pigmentation such that pulse oximetry will overestimate oxygenation in newborns with darker skin. The main questions it aims to answer is if SaO2-SpO2 discrepancy varies with the degree of skin pigmentation among neonates, if gestational age has an influence on SaO2-SpO2 discrepancy, and if packed red blood cell (PRBC) transfusion has an influence on SaO2-SpO2 discrepancy in newborns with various degrees of light and dark skin. Researchers will compare SaO2 and SpO2 values in neonates of various skin pigmentation.

Read the detailed description

Investigators will use a multicenter prospective cohort approach to measure SpO2 and SaO2 simultaneously in newborns of varying degrees of light and dark skin. The investigators will enroll 163 newborns of varying degrees of light and dark skin to assess the impact of skin pigmentation on the accuracy of pulse oximetry. Data collection will occur during routine blood samples and will involve simultaneous measurement of oxygen saturation by pulse oximetry and additional data extraction from the EHR. The study consists of 4 main components: (1) Skin pigment classification (2) Race and ethnicity classification (3) SpO2 measurement collection (4) EMR data collection (including newborn screen hemoglobin type assessment and transfusion records). After adjusting for SaO2, the SaO2-SpO2 discrepancy will correlate with skin pigmentation such that pulse oximetry will overestimate oxygenation in newborns with darker skin. The distribution of SaO2-SpO2 discrepancy will have more variance in the newborns with darker skin.

03

Conditions studied

  • Skin Pigment
  • Pulse Oximetry

Browse trials for

04

Who can participate

Ages eligible
Up to 10 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns postnatal age \< 10 days admitted to intensive care unit
  • Presence of arterial catheter or undergoing arterial stick blood gas sampling

Exclusion criteria

Exclusion Criteria:

  • \<26 weeks corrected gestational age (After May 2024, infants \<26 weeks corrected GA were excluded due to skin irritation with sensor removal, those enrolled earlier were included in the analysis)
  • Presence of abnormal (including methemoglobin > 3%) - likely to only be known after enrolled and the blood gas is obtained
  • Those in whom SpO2 cannot be measured in the same extremity as the arterial catheter.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
163 participants (estimated)

Study arms

  • Experimental
    Enrolled Participant

    During routine arterial blood gas sampling, a coordinator will measure SpO2 from a similar extremity. SpO2 data will be recorded using Masimo Radical-7 oximeters. To minimize ambient light interference or optical cross talk from other SpO2 sensors, all the SpO2 sensors will be fully shielded with cloth wraps provided by Masimo. Each enrolled infant will undergo simultaneous blood gas sampling and SpO2 measurement for each routine blood gas collected. Up to a total of 10 SpO2 measurements will be collected, paired with 10 blood gas samples collected as part of routine care, though We anticipate about 3 paired samples (SaO2 and SpO2) per enrolled infant.

    Device: Enrolled Participant

Interventions

  • DeviceEnrolled Participant

    Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.

06

What researchers measure

Primary outcomes

  1. Determine if SaO2-SpO2 discrepancy varies with the degree of skin pigmentation among neonates.

    Using a prospective cohort of 163 newborns, the investigators will calculate simultaneous SaO2-SpO2 discrepancy and correlate it with a measure of skin pigmentation (melanin index: Fitzpatrick Scale, Massey-Martin scale and ITA: individual Typology Angle) among neonates with and without hypoxemia.

    Time frame: Through study completion, about 2 years

  2. Determine the influence of packed red blood cell (PRBC) transfusion on SaO2-SpO2 discrepancy in newborns with various degrees of light and dark skin.

    Many infants in the NICU setting are transfused PRBC with hemoglobin A, which shifts the oxygen-hemoglobin dissociation curve to the right. While the effect of this shift on pulse oximetry is studied, the combined impact of skin pigmentation and transfusion is not known. The investigators will test the hypothesis that PRBC transfusion increases the impact of skin pigmentation on SaO2- SpO2 discrepancy. The investigators will calculate the SaO2-SpO2 discrepancy and correlate it with the skin pigmentation measurement and frequency of PRBC transfusion.

    Time frame: Through study completion, about 2 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 56 months after the start.

Of 21 interventional studies with no phase under Pigmentation Disorders, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Oct 2, 2023
StartActual
Apr 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063148
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Apr 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion